Integrating emerging treatment options in mantle cell lymphoma: introduction.
Mantle cell lymphoma (MCL) is a unique subtype of non-Hodgkin lymphoma (NHL). MCL accounts for approximately 6% of new lymphoma cases each year.1 Because it is a relatively uncommon form of lymphoma, it is more difficult to study than other lymphoma subtypes. There are many single-arm, phase 2 trials in the MCL literature, but there is a relative paucity of large, randomized, phase 3 trials. As a result, comparisons are often made across trials, and observations are based on extrapolation.